LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 286

Search options

  1. Book: Pharmacological properties of plant-derived natural products and implications for human health

    Barreto, George E. / Sahebkar, Amirhossein

    (Advances in experimental medicine and biology ; volume 1308)

    2021  

    Author's details George Barreto, Amirhossein Sahebkar editors
    Series title Advances in experimental medicine and biology ; volume 1308
    Collection
    Language English
    Size x, 603 Seiten, Illustrationen
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book
    HBZ-ID HT020905756
    ISBN 978-3-030-64871-8 ; 9783030648725 ; 3-030-64871-0 ; 3030648729
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Repurposing of Tibolone in Alzheimer's Disease.

    Barreto, George E

    Biomolecules

    2023  Volume 13, Issue 7

    Abstract: Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterised by the accumulation of amyloid-beta and tau in the brain, leading to the progressive loss of memory and cognition. The causes of its pathogenesis are still not fully ... ...

    Abstract Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterised by the accumulation of amyloid-beta and tau in the brain, leading to the progressive loss of memory and cognition. The causes of its pathogenesis are still not fully understood, but some risk factors, such as age, genetics, and hormones, may play a crucial role. Studies show that postmenopausal women have a higher risk of developing AD, possibly due to the decrease in hormone levels, especially oestrogen, which may be directly related to a reduction in the activity of oestrogen receptors, especially beta (ERβ), which favours a more hostile cellular environment, leading to mitochondrial dysfunction, mainly affecting key processes related to transport, metabolism, and oxidative phosphorylation. Given the influence of hormones on biological processes at the mitochondrial level, hormone therapies are of clinical interest to reduce the risk or delay the onset of symptoms associated with AD. One drug with such potential is tibolone, which is used in clinics to treat menopause-related symptoms. It can reduce amyloid burden and have benefits on mitochondrial integrity and dynamics. Many of its protective effects are mediated through steroid receptors and may also be related to neuroglobin, whose elevated levels have been shown to protect against neurological diseases. Its importance has increased exponentially due to its implication in the pathogenesis of AD. In this review, we discuss recent advances in tibolone, focusing on its mitochondrial-protective effects, and highlight how valuable this compound could be as a therapeutic alternative to mitigate the molecular pathways characteristic of AD.
    MeSH term(s) Female ; Humans ; Alzheimer Disease/metabolism ; Neurodegenerative Diseases/metabolism ; Drug Repositioning ; Amyloid beta-Peptides/metabolism ; Estrogens
    Chemical Substances tibolone (FF9X0205V2) ; Amyloid beta-Peptides ; Estrogens
    Language English
    Publishing date 2023-07-13
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom13071115
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: An analysis of omega-3 clinical trials and a call for personalized supplementation for dementia prevention.

    Castellanos-Perilla, Nicolás / Borda, Miguel Germán / Aarsland, Dag / Barreto, George E

    Expert review of neurotherapeutics

    2024  Volume 24, Issue 3, Page(s) 313–324

    Abstract: Introduction: Targeted interventions are needed to delay or prevent the onset of neurodegenerative diseases. Poor dietary habits are associated with cognitive decline, highlighting the benefits of a healthy diet with fish and polyunsaturated fatty acids ...

    Abstract Introduction: Targeted interventions are needed to delay or prevent the onset of neurodegenerative diseases. Poor dietary habits are associated with cognitive decline, highlighting the benefits of a healthy diet with fish and polyunsaturated fatty acids (PUFAs). Intake of omega-3 PUFAs docosahexaenoic acid (DHA), α-linolenic acid (ALA) and eicosapentaenoic acid (EPA) is linked with healthy aging, cardiovascular benefits, and reduced risk of Alzheimer's disease. Although omega-3 has health benefits, its intake is often inadequate and insufficient in modern diets. Although fish oil supplements offer an alternative source, inconsistent results from clinical trials raise questions about the factors determining their success.
    Areas covered: In this this review, the authors discuss the aforementioned determining factors and highlight strategies that could enhance the effectiveness of omega-3 PUFAs interventions for dementia and cognitive decline. Moreover, the authors provide suggestions for potential future research.
    Expert opinion: Factors such as diet, lifestyle, and genetic predisposition can all influence the effectiveness of omega-3 supplementation. When implementing clinical trials, it is crucial to consider these factors and recognize their potential impact on the interpretation of results. It is important to study each variable independently and the interactions between them.
    MeSH term(s) Humans ; Fatty Acids, Omega-3/therapeutic use ; Eicosapentaenoic Acid/therapeutic use ; Docosahexaenoic Acids/therapeutic use ; Dietary Supplements ; Dementia/prevention & control ; Dementia/drug therapy
    Chemical Substances Fatty Acids, Omega-3 ; Eicosapentaenoic Acid (AAN7QOV9EA) ; Docosahexaenoic Acids (25167-62-8)
    Language English
    Publishing date 2024-02-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2112534-X
    ISSN 1744-8360 ; 1473-7175
    ISSN (online) 1744-8360
    ISSN 1473-7175
    DOI 10.1080/14737175.2024.2313547
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Sex-specific vulnerabilities in human astrocytes underpin the differential impact of palmitic acid.

    Hidalgo-Lanussa, Oscar / González Santos, Janneth / Barreto, George E

    Neurobiology of disease

    2024  Volume 195, Page(s) 106489

    Abstract: Obesity and neurometabolic diseases have been linked to neurodegenerative diseases. Our hypothesis is that the endogenous estrogenic component of human astrocytes plays a critical role in cell response during lipotoxic damage, given that obesity can ... ...

    Abstract Obesity and neurometabolic diseases have been linked to neurodegenerative diseases. Our hypothesis is that the endogenous estrogenic component of human astrocytes plays a critical role in cell response during lipotoxic damage, given that obesity can disrupt hormonal homeostasis and cause brain inflammation. Our findings showed that high concentrations of palmitic acid (PA) significantly reduced cell viability more in male astrocytes, indicating sex-specific vulnerabilities. PA induced a greater increase in cytosolic reactive oxygen species (ROS) production in males, while female astrocytes exhibited higher superoxide ion levels in mitochondria. In addition, female astrocytes treated with PA showed increased expression of antioxidant proteins, including catalase, Gpx-1 and Nrf2 suggesting a stronger cellular defence mechanism. Interestingly, there was a difference in the expression of estrogenic components, such as estrogen, androgens, and progesterone receptors, as well as aromatase and 5α-reductase enzymes, between males and females. PA induced their expression mainly in females, indicating a potential protective mechanism mediated by endogenous hormones. In summary, our findings highlight the impact of sex on the response of human astrocytes to lipotoxicity. Male astrocytes appear to be more susceptible to cellular damage when exposed to high concentrations of fatty acids.
    MeSH term(s) Humans ; Astrocytes/metabolism ; Astrocytes/drug effects ; Palmitic Acid/pharmacology ; Palmitic Acid/toxicity ; Female ; Male ; Reactive Oxygen Species/metabolism ; Sex Characteristics ; Cell Survival/drug effects ; Cell Survival/physiology ; Cells, Cultured ; NF-E2-Related Factor 2/metabolism ; Glutathione Peroxidase/metabolism ; Catalase/metabolism ; Aromatase/metabolism ; Oxidative Stress/drug effects ; Oxidative Stress/physiology ; Mitochondria/metabolism ; Mitochondria/drug effects ; Glutathione Peroxidase GPX1
    Chemical Substances Palmitic Acid (2V16EO95H1) ; Reactive Oxygen Species ; NFE2L2 protein, human ; NF-E2-Related Factor 2 ; Glutathione Peroxidase (EC 1.11.1.9) ; GPX1 protein, human (EC 1.11.1.9) ; Catalase (EC 1.11.1.6) ; Aromatase (EC 1.14.14.1) ; Glutathione Peroxidase GPX1 (EC 1.11.1.9)
    Language English
    Publishing date 2024-03-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1211786-9
    ISSN 1095-953X ; 0969-9961
    ISSN (online) 1095-953X
    ISSN 0969-9961
    DOI 10.1016/j.nbd.2024.106489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Comparison of Antioxidant Capacity and Network Pharmacology of Phloretin and Phlorizin against Neuroinflammation in Traumatic Brain Injury.

    Ongay, Kubra Kizil / Granato, Daniel / Barreto, George E

    Molecules (Basel, Switzerland)

    2023  Volume 28, Issue 3

    Abstract: Neuroinflammation is a hallmark of traumatic brain injury (TBI)'s acute and chronic phases. Despite the medical and scientific advances in recent years, there is still no effective treatment that mitigates the oxidative and inflammatory damage that ... ...

    Abstract Neuroinflammation is a hallmark of traumatic brain injury (TBI)'s acute and chronic phases. Despite the medical and scientific advances in recent years, there is still no effective treatment that mitigates the oxidative and inflammatory damage that affects neurons and glial cells. Therefore, searching for compounds with a broader spectrum of action that can regulate various inflammatory signaling pathways is of clinical interest. In this study, we determined not only the in vitro antioxidant capacity of apple pomace phenolics, namely, phlorizin and its metabolite, phloretin, but we also hypothesize that the use of these bioactive molecules may have potential use in TBI. We explored the antioxidant effects of both compounds in vitro (DPPH, iron-reducing capacity (IRC), and Folin-Ciocalteu reducing capacity (FCRC)), and using network pharmacology, we investigated the proteins involved in their protective effects in TBI. Our results showed that the antioxidant properties of phloretin were superior to those of phlorizin in the DPPH (12.95 vs. 3.52 mg ascorbic acid equivalent (AAE)/L), FCRC (86.73 vs. 73.69 mg gallic acid equivalent (GAE)/L), and iron-reducing capacity (1.15 vs. 0.88 mg GAE/L) assays. Next, we examined the molecular signature of both compounds and found 11 proteins in common to be regulated by them and involved in TBI. Meta-analysis and GO functional enrichment demonstrated their implication in matrix metalloproteinases, p53 signaling, and cell secretion/transport. Using MCODE and Pearson's correlation analysis, a subcluster was generated. We identified ESR1 (estrogen receptor alpha) as a critical cellular hub being regulated by both compounds and with potential therapeutic use in TBI. In conclusion, our study suggests that because of their vast antioxidant effects, probably acting on estrogen receptors, phloretin and phlorizin may be repurposed for TBI treatment due to their ease of obtaining and low cost.
    MeSH term(s) Humans ; Antioxidants/metabolism ; Phloretin/pharmacology ; Phlorhizin/pharmacology ; Neuroinflammatory Diseases ; Network Pharmacology ; Brain Injuries, Traumatic/drug therapy ; Iron
    Chemical Substances Antioxidants ; Phloretin (S5J5OE47MK) ; Phlorhizin (CU9S17279X) ; Iron (E1UOL152H7)
    Language English
    Publishing date 2023-01-17
    Publishing country Switzerland
    Document type Meta-Analysis ; Journal Article
    ZDB-ID 1413402-0
    ISSN 1420-3049 ; 1431-5165 ; 1420-3049
    ISSN (online) 1420-3049
    ISSN 1431-5165 ; 1420-3049
    DOI 10.3390/molecules28030919
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Network pharmacology and topological analysis on tibolone metabolites and their molecular mechanisms in traumatic brain injury.

    Barreto, George E / Gonzalez, Janneth / Ramírez, David

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2023  Volume 165, Page(s) 115089

    Abstract: Traumatic brain injury (TBI) is a pathology of great social impact, affecting millions of people worldwide. Despite the scientific advances to improve the management of TBI in recent years, we still do not have a specific treatment that controls the ... ...

    Abstract Traumatic brain injury (TBI) is a pathology of great social impact, affecting millions of people worldwide. Despite the scientific advances to improve the management of TBI in recent years, we still do not have a specific treatment that controls the inflammatory process after mechanical trauma. The discovery and implementation of new treatments is a long and expensive process, making the repurpose of approved drugs for other pathologies a clinical interest. Tibolone is a drug in use for the treatment of symptoms associated with menopause and has been shown to have a broad spectrum of actions by regulating estrogen, androgen and progesterone receptors, whose activation exerts potent anti-inflammatory and antioxidant effects. In the present study, we aimed to investigate the therapeutic potential of the tibolone metabolites 3α-Hydroxytibolone, 3β-Hydroxytibolone, and Δ4-Tibolone as a possible therapy in TBI using network pharmacology and network topology analysis. Our results demonstrate that the estrogenic component mediated by the α and β metabolites can regulate synaptic transmission and cell metabolism, while the Δ metabolite may be involved in modulating the post-TBI inflammatory process. We identified several molecular targets, including KDR, ESR2, AR, NR3C1, PPARD, and PPARA, which are known to play critical roles in the pathogenesis of TBI. Tibolone metabolites were predicted to regulate the expression of key genes involved in oxidative stress, inflammation, and apoptosis. Overall, the repurposing of tibolone as a neuroprotective treatment for TBI holds promise for future clinical trials. However, further studies are needed to confirm its efficacy and safety in TBI patients.
    MeSH term(s) Female ; Humans ; Network Pharmacology ; Estrogens/metabolism ; Estrogen Receptor Modulators/pharmacology ; Brain Injuries, Traumatic/drug therapy
    Chemical Substances tibolone (FF9X0205V2) ; Estrogens ; Estrogen Receptor Modulators
    Language English
    Publishing date 2023-07-06
    Publishing country France
    Document type Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2023.115089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Gonadal hormone deprivation regulates response to tibolone in neurodegenerative pathways.

    McGovern, Andrew J / Arevalo, Maria Angeles / Ciordia, Sergio / Garcia-Segura, Luis Miguel / Barreto, George E

    The Journal of steroid biochemistry and molecular biology

    2024  Volume 241, Page(s) 106520

    Abstract: Gonadal hormone deprivation (GHD) and decline such as menopause and bilateral oophorectomy are associated with an increased risk of neurodegeneration. Yet, hormone therapies (HTs) show varying efficacy, influenced by factors such as sex, drug type, and ... ...

    Abstract Gonadal hormone deprivation (GHD) and decline such as menopause and bilateral oophorectomy are associated with an increased risk of neurodegeneration. Yet, hormone therapies (HTs) show varying efficacy, influenced by factors such as sex, drug type, and timing of treatment relative to hormone decline. We hypothesize that the molecular environment of the brain undergoes a transition following GHD, impacting the effectiveness of HTs. Using a GHD model in mice treated with Tibolone, we conducted proteomic analysis and identified a reprogrammed response to Tibolone, a compound that stimulates estrogenic, progestogenic, and androgenic pathways. Through a comprehensive network pharmacological workflow, we identified a reprogrammed response to Tibolone, particularly within "Pathways of Neurodegeneration", as well as interconnected pathways including "cellular respiration", "carbon metabolism", and "cellular homeostasis". Analysis revealed 23 proteins whose Tibolone response depended on GHD and/or sex, implicating critical processes like oxidative phosphorylation and calcium signalling. Our findings suggest the therapeutic efficacy of HTs may depend on these variables, suggesting a need for greater precision medicine considerations whilst highlighting the need to uncover underlying mechanisms.
    Language English
    Publishing date 2024-04-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 1049188-0
    ISSN 1879-1220 ; 0960-0760
    ISSN (online) 1879-1220
    ISSN 0960-0760
    DOI 10.1016/j.jsbmb.2024.106520
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book ; Online: Cerebral endothelial and glial cells are more than bricks in the Great Wall of the brain: Insights into the way the blood-brain barrier actually works (Celebrating the centenary of Goldmans experiments)

    Bacha, Ramon Santos El / Guedes, Rubem C A / Agundez, Jose A G / Barreto, George E. / Martin, Elena Garcia

    2015  

    Abstract: When Ehrlich discovered the first evidence of the blood-brain barrier in 1885, he probably did not perceive the Great Wall that remained hidden from consciousness inside the central nervous system. Ehrlich had observed that acidic vital dyes did not ... ...

    Abstract When Ehrlich discovered the first evidence of the blood-brain barrier in 1885, he probably did not perceive the Great Wall that remained hidden from consciousness inside the central nervous system. Ehrlich had observed that acidic vital dyes did not stain the brain if they were injected into the blood stream. A century ago (1913), Goldman showed that the injection of trypan blue in the cerebrospinal fluid stained only the brain, but not the other organs. For almost a century it was thought that the blood-brain barrier (BBB) consisted in a physical barrier, resulting from the restricted permeability of the cerebral endothelial cell layer, as they are joined by tight junctions. However, as scientists are always looking for news in what is already discovered, in the end of the 20th century we had evidences that cerebral endothelial and glial cells express several drug metabolizing enzymes consisting in a second protection system: a metabolic barrier.-

    Furthermore, the drugs and their metabolites must overcome the activity of several multidrug resistance proteins that function as ATP-dependent efflux pumps, consisting in the third line of defence: the active barrier. Therefore, the way the BBB actually works should be better explained. Several endogenous compounds, as well as xenobiotics, may be activated by enzymes of the metabolic barrier, generating reactive oxygen species that could damage neurons. Therefore, endothelial and glial cells possess endogenous protecting compounds and enzymes against oxidants, consisting in an antioxidant barrier. When all these systems fail, glial cells, mainly microglia, secrete cytokines in an attempt to crosstalk with defence cells asking for help, which consists in an immune barrier. In cerebral regions that are devoid of the physical barrier, such as circumventricular organs, the metabolic, active, antioxidant and immune barriers are reinforced.-

    It is important to understand how cells involved in the BBB interact with one another and the dynamic mechanisms of their functions. This Research Topic published in this e-Book considers recent highlights in BBB structure, cell and molecular biology, biotransformation, physiology, pathology, pharmacology, immunology and how these basic knowledges can be applied in drug discovery and clinical researches, rewriting what is already written, and paving the way that goes to the Great Wall in the Frontiers of the Brain in this new century that is just beginning
    Keywords Neurosciences. Biological psychiatry. Neuropsychiatry ; Science (General)
    Size 1 electronic resource (186 p.)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT020090880
    ISBN 9782889195725 ; 2889195724
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  9. Article ; Online: Nano-Nutraceuticals Dietary Supplements for Athletes: An Eminent Approach for Managing Traumatic Brain Injuries.

    Javed, Noushad / Pottoo, Faheem Hyder / Barreto, George E

    Current molecular pharmacology

    2022  Volume 15, Issue 1, Page(s) 1–2

    MeSH term(s) Athletes ; Brain Injuries, Traumatic/drug therapy ; Dietary Supplements ; Humans
    Language English
    Publishing date 2022-03-11
    Publishing country United Arab Emirates
    Document type Editorial
    ISSN 1874-4702
    ISSN (online) 1874-4702
    DOI 10.2174/1874467215666220104212247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Exploration of novel ligands to target C-C Motif Chemokine Receptor 2 (CCR2) as a promising pharmacological treatment against traumatic brain injury.

    Sachdev, Kilian R / Lynch, Kevin J / Barreto, George E

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2022  Volume 151, Page(s) 113155

    Abstract: It is widely reported that the overexpression of the C-C Motif Chemokine Receptor 2 (CCR2) has negative implications in neuroinflammatory diseases such as traumatic brain injury (TBI), although promising drugs to tackle this have been less forthcoming. ... ...

    Abstract It is widely reported that the overexpression of the C-C Motif Chemokine Receptor 2 (CCR2) has negative implications in neuroinflammatory diseases such as traumatic brain injury (TBI), although promising drugs to tackle this have been less forthcoming. As of 2016, only 2 drugs specifically targeting this receptor have made their way to market, with unsuccessful outcome unfortunately, suggesting that the search for more specific and precise ligands is utterly necessary. In this paper we hypothesized that by targeting Glu291, Met295, Trp98, Leu45 and Val189 amino acids, essential in the binding of CCR2 with C-C Motif Chemokine Ligand 2 (CCL2), the endogenous substrate, mitigates its activity in TBI. We used a pharmacophore model to screen for suitable ligands that may bind to CCR2, which returned 871 ligands. Docking and molecular dynamics results uncovered that two ligands (A102) and (A435) contained several of those important residues and showed a stability and compactness when in complex with CCR2, with these results confirmed by MMGBSA calculations with A102 recording a better interaction compared to A435. Finally, a PPI network was built to explore downstream signaling being regulated by both ligands in TBI, showing amyloid precursor protein (APP) as a key target and neuroactive-ligand receptor interaction (1.80E-27) the top functional annotated category. In conclusion, for the first time we report novel ligands A102 and A435 targeting CCR2 as a potential new pharmacological approach to target inflammation post-TBI.
    MeSH term(s) Brain Injuries, Traumatic/drug therapy ; Chemokine CCL2/metabolism ; Humans ; Inflammation ; Ligands ; Receptors, CCR2/metabolism ; Signal Transduction
    Chemical Substances CCR2 protein, human ; Chemokine CCL2 ; Ligands ; Receptors, CCR2
    Language English
    Publishing date 2022-05-20
    Publishing country France
    Document type Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2022.113155
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top